Rheumatology

Article	Citations
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	148
Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	105
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	95
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	76
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	63
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	63
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	62
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	58
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	58
Boxer’s shape, an unusual finding in nailfold capillaroscopy	56
Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers—an observational study	54
Editor’s Acknowledgement	54
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort	51
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	51
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	49
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	48
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	47
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	46
Negative back beliefs are associated with increased odds of low back pain and disability: a 10-year cohort study in men	46
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis	46
Soluble BDCA-2 as a potential biomarker for rheumatoid arthritis and its role in enhancing IFN-α production through nucleic acid binding	45
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study	44
OA22 Methotrexate drug monitoring and referral patterns to Hepatology - can we improve detection and monitoring of hepatoxicity with methotrexate use?	44
Impaired humoral and T helper cell responses to toxic shock syndrome toxin-1 (TSST-1) in granulomatosis with polyangiitis	43
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort	42

Giant cell arteritis of the prostate	42
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	41
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity	41
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	41
Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy	41
P011 Rituximab and COVID-19 vaccines; are they fit for purpose?	40
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	40
Type I interferon dysregulation drives distinct pathogenic pathways in early- and late-onset lupus nephritis	40
Comment on: Predictors of lack of response to methotrexate in juvenile idiopathic arthritis–associated uveitis	40
The state of data sharing in rheumatology: a systematic review of top journal practices	39
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	39
OA44 Increasing access to rehabilitation for knee and hip osteoarthritis - ESCAPE-pain in leisure/community centres	38
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	38
E046 Lytic lesions; metastatic disease or gout?	38
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	38
P114 Medication adherence to b/tsDMARDS remains sub-optimal in refractory rheumatoid arthritis	38
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	38
P131 Adult coeliac disease and bone mineral density at the femoral neck, total hip and lumbar spine: an age- and sex-matched case-control study	38
P083 Undergraduate rheumatology teaching in the UK: a survey of teachers	37
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	36
P073 Functional investigation of Osteoarthritis-associated non-coding variants using CRISPR/Cas9-mediated perturbation of active enhancer regions	36
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	36
P143 Frailty is associated with inflammation, impaired glucose metabolism and reduced bone mineral density after adjustment for fat mass index: a UK biobank study	36
E051 Audit of the management of patients over 75 with osteoporotic fragility fractures in primary care	35
P041 Successful reversal of microvascular damage with standard therapy in a case of dermatomyositis overlap syndrome	35
P033 The intriguing association between fibromyalgia, hypermobility and neurodivergence: a pilot study	35
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	34
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	34
26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	34
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	33
OA04 COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a national cohort	32
P004 Empowering the reproductive choices of patients with rheumatic disease: using the BSR 2022 pregnancy guidelines audit tool to evaluate pre-conception medication advice	32
P077 Developing a better explanation of osteoarthritis: results from a conjoint analysis of patient preferences	32
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years	31
P185 Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index	31
P179 A feasibility randomised controlled trial of a fibromyalgia self-management programme in a community setting with a nested qualitative study	31
Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis	31
P004 Temporal and regional variation in the initiation of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study	31
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	31
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	30
P174 Identifying patterns of fatigue across flares in patients with axial spondyloarthritis	30
54 Kawasaki disease: experience in a general paediatric department of the CHU de Annaba Algeria	30
P133 Experiences of people with digital ulcers through filmed interviews	30
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals	30
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	30
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease	30
Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib	29
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	29
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib	29
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment	29

Bezoar secondary to NSAID use in a patient with inflammatory arthritis	28
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis	28
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	28
The usefulness of ultrasound in predicting outcomes in patients with shoulder pain: a prospective observational study	28
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus	27
The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial	27
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	27
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?	27
IGFBP5 regulates fibrocartilage differentiation and cartilage injury induced by T-2 toxin via blocking IGF-1/IGF-1R signalling	27
High levels of EPSTI1 enhance IFN-β-mediated HLA-A expression and chemokine secretion in myoblasts in dermatomyositis	27
Lupus serology: off target but still relevant to the treat-to-target strategy in systemic lupus erythematosus	27
Avacopan may not independently reduce ANCA titres in ANCA-associated vasculitis: a retrospective analysis of 57 patients	27
Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests	27
P261 Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom	27
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study	26
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE	26
Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status	26
VEXAS syndrome mimicking lupus-like disease	26
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	26
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review	26
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?	26
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis	26
Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry	26
Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study	25
Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3	25
Clinician views concerning the prevalence and impact of granulomas on the diagnosis, management, and outcomes of ANCA-associated vasculitis	25
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	25
Oesophageal dysmotility patterns are associated with distinct clinical phenotypes and prognosis in patients with systemic sclerosis	25
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE	25
Correction to: TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis	24
Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases	24
Osteophytes’ position in subjects with DISH and right-sided aorta: verification of the ‘aortic pulsation protective effect’ theory	24
Examination of nailfold videocapillaroscopy findings in ANCA-associated vasculitis	24
A Child with CANDLE Syndrome Presenting as Seronegative Polyarthritis Following Early Chemotherapy	24
Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis	24
The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus	24
Giant thymic cyst overclouding the diagnosis of fibrodysplasia ossificans progressiva: an inconvenient coincidence	24
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet’s disease versus the general population	24
The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership	24
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis	24
Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study	24
Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic and imaging associations	24
Interplay between genetics and lifestyle on pain susceptibility in women with fibromyalgia: the al-Ándalus project	24
Enhancing diagnosis of gout with deep learning in dual-energy computed tomography: a retrospective analysis of crystal and artefact differentiation	24
Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis	24
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis	24
Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis	24
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	24
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances	23
Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort	23
E68 Kawasaki Disease before and during COVID-19	23
P110 Characteristics of Difficult to treat Rheumatoid Arthritis patients in a large District Hospital in the UK	23
OA06 Single-centre experience of the use of Rituximab for inflammatory arthritis during the COVID-19 pandemic	23
P027 Infliximab in the treatment of cerebral tuberculosis paradoxical reactions with vasculitis	23
Comment on: Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports	23
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	23
E71 Distribution of cells and extracellular matrix in the normal marginal synovium of the hip joint capsule during the postnatal period	23
OA01 Cluster medicine: the role of genetics for identifying shared biological pathways between rheumatoid arthritis and common comorbidities for targeting treatments	23
OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study	23
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry)	23
P208 PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population	23
P133 Attitudes to Technology supported Rheumatoid Arthritis care: Opportunities & Barriers for technology in RA - Key themes from Qualitative arm of Mixed-Methods Study	23
P046 The influence of deprivation in the outcomes of Psoriatic Arthritis within the UK - utilising Outcomes of Treatment in Psoriatic Arthritis Study Syndicate data	23
20 Does hip involvement affect foot and ankle in juvenile idiopathic arthritis?	23
64 Conical teeth? Think outside the box!	22
P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome	22
E005 Investigation into the post-diagnostic care and follow-up of patients with giant cell arteritis post-initiation of long-term glucocorticoids at University Hospitals Leicester NHS Foundation Trust	22
P212 Understandings and responses to joint pain: preliminary findings from a rapid ethnographic assessment in Northern Tanzania	22
OA28 VEXAS, a service evaluation in Rheumatology at Sheffield: “Seek, and ye shall find”	22
Multicentric Castleman disease presenting with frequent urination	22
P163 The cytokine horror: Kawasaki disease shock syndrome complicated with macrophage activation syndrome	22
P038 The importance of looking carefully for the cause(s)	22
P229 Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis	22
P303 Development of a Behçet’s disease specific patient concerns inventory	21
56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy	21
P094 Experts in lived experience: CLUSTER Champions and their successful collaboration in JIA research	21
Assessing the role of climate and the environment as co-factors for vasculitis diseases	21
P055 Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum	21
P012 Pneumocystis jirovecii pneumonia in rheumatology patients - a single centre ten-year audit	21
E001 Pre-screen chest X-ray before starting methotrexate in autoimmune disease	21

P127 A retrospective cohort study assessing outcomes and safety in patients receiving low dose vs high dose cyclophosphamide in myositis interstitial lung disease	21
P117 Remote monitoring of rheumatoid arthritis using RAPID3 to support patient-initiated follow up	21
E005 An audit of demographics, symptoms & investigations: Part of the survey of GCA in the SEHSCT during the COVID-19 pandemic	21
61 The nailfold videocapillaroscopy in pediatric Behçet’s disease: a multi-center study	21
P247 Novel therapeutic peptides targeting CD206 modulate ATP-induced release of inflammatory and B cell activating factors in lupus macrophages	21
P081 Is it necessary to test vitamin D prior to zoledronate or denosumab treatment?	21
Nailfold videocapillaroscopy findings correlate with lung outcomes in idiopathic inflammatory myopathies–related interstitial lung disease	20
Experience with upadacitinib in refractory polyarticular juvenile idiopathic arthritis	20
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis	20
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews	20
Use of primary health care and radiological imaging preceding a diagnosis of rheumatoid arthritis: a nationwide cohort study in Denmark	20
Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study	20
Emerging targeted therapies in ANCA-associated vasculitis	20
Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study	20
Tofacitinib as a possible treatment for arthritis in an APDS2 patient	20
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles	20
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study	20
Correction to: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis	20
Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease?	20
Correction to: Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region	20
History of tonsillectomy is associated with glandular inflammation in Sjögren’s disease	20
Physical activity in relation to the risk of systemic lupus erythematosus: a prospective study including 401 745 individuals	20
A case of hypertrophic pachymeningitis with neutrophil extracellular traps formation	19
When should we start screening for hydroxychloroquine retinopathy?	19
Quantitative chest imaging and prediction of mortality in rheumatoid arthritis–associated interstitial lung disease	19
Comment on: Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk: reply	19
Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry	19
Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study	19
Erratum to: Parvovirus B19 induces cellular senescence in human dermal fibroblasts: putative role in systemic sclerosis-associated fibrosis	19
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis	19
IFN-α levels correlate with muscle disease activity only in juvenile dermatomyositis patients with anti-MDA5+ autoantibodies	19
Predicting treatment response to methotrexate: are we closer to solving the enigma?	19
Registry based studies on pregnancy and rheumatic diseases: generating actionable evidence	19
Raynaud’s phenomenon and digital ischaemia induced by ixekizumab	19
Avacopan in an ocular complication of ANCA-PR3 vasculitis without kidney involvement	19
E044 Telephone clinic consultations in the COVID-19 era: the rates of conversion to face-to-face appointments and discharges in the post-pandemic years	18
P113 Cellular profiling of synovial fluid in inflammatory arthritis highlights disease-specific cell states with biological and diagnostic relevance	18
P293 Tocilizumab for refractory or relapsing giant cell arteritis: audit data from the Bristol and Bath regional multidisciplinary meetings 2018-2021	18
P177 Investigating the neural differences in individuals with chronic widespread pain or fibromyalgia and the effect of sleep: a cross-sectional study using data from UK Biobank	18
E048 A review of published data on reported staffing ratios for rheumatology specialist physiotherapists in rheumatology departments	18
P301 Patient reported outcome measure for giant cell arteritis: clinical testing	18
E29 Juvenile Idiopathic Arthritis (JIA) in Algeria, from diagnosis to management	18
P274 The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDs, at 52 weeks in pa	18
P133 Anti-synthetase syndrome: an experience from a tertiary referral center	18
P257 Are there regional variations in access to biological disease modifying anti-rheumatic drugs for the treatment of psoriatic arthritis in England?	18
P296 Giant cell arteritis/large vessel vasculitis with normal inflammatory markers: a case series of 15 patients in south Manchester	18
P039 Haemophagocytic lymphohistiocytosis secondary to invasive aspergillosis in a patient with undiagnosed SLE	18
OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications	18
P156 Type I interferon is raised across connective tissue diseases and is associated with haematological abnormalities and specific autoantibody profiles	18
P106 Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial	18
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study	17
P123 Biologic dose tapering: a patient perspective	17
P278 Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis patients through 52 weeks: data from three phase III,	17
Upadacitinib in the treatment of Takayasu arteritis: a case report on new perspectives on targeted immunomodulation	17
P284 Evaluation of a self-management smartphone app for those living with Sjögren’s syndrome: a fully remote randomised pilot and feasibility trial	17
Risk of venous thromboembolism in people with RA: a population-based study in the UK	17
Citrate in the management of gout, urate nephrolithiasis and kidney disease: an old therapy rediscovered?	17
P066 Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients	17
P130 Pharmacist-led osteoporosis telephone service	17
77 Case series of juvenile scleroderma from Nigeria	17
Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthri	17
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study	17
It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis	17
P139 Impact of hand function impairment on daily life of patients with systemic sclerosis - a qualitative study	17
P167 COVID-19 perniosis, a differential diagnosis to consider in adolescent patients presenting with chilblain-like lesions	17
Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down	17
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry	17
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care	17
Increased risk of myocarditis and arrythmias in anti-Ku-positive scleroderma–myositis overlap patients: a case series	17
Where are we now in biologic drugs for myositis?	16
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate	16
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment	16
COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis	16
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study	16
Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus–associated refractory cerebral vasculitis induces immune tolerance	16
Fibroblast activation protein inhibitor positron emission tomography imaging in muscles of patients with idiopathic inflammatory myopathy	16
Sarcoid myopathy: an insidious diagnosis that can mimic inclusion body myositis	16
Is the relationship between deprivation and outcomes in rheumatoid arthritis mediated by body mass index? A longitudinal cohort study	16
Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome	16
Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients	16
Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study	16
HLA-C*06–defined endotype in psoriatic disease: an ever-widening landscape	16
Use of sarilumab in VEXAS syndrome	16
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease	16
Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease	16
Teledidactic peer-tutored musculoskeletal ultrasound training for medical students—the TELMUS study	16
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis	16
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease	16
Fine particulate matter air pollution and anti-nuclear antibodies	16
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders	16
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation	16
Transiently increased circulating CD39+FoxP3+ Treg cells predicts the clinical response to methotrexate in early rheumatoid arthritis	16
The SUMO components in rheumatoid arthritis	16
E047 Utilization of complementary and alternative medicine in patients with rheumatological conditions at Kenyatta National Hospital	15
P162 Investigating triggers, preventers, and progression of symptoms in flares of systemic autoimmune rheumatic diseases: a mixed methods study	15